The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count

AIDS

Volumn 12, Issue 5, 1998, Pages

  Montaner, Julio S G ^a   DeMasi, Ralph ^b   Hill, Andrew M ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antiviral therapy; CD4 cell count; Disease progression; Viral load

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; LOVIRIDE; PLACEBO; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

ACETAMIDES; ACETOPHENONES; ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; ZALCITABINE; ZIDOVUDINE;

EID: 0032568194     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199805000-00003     Document Type: Article

References (16)

1. Mellors JW, Munoz A, Giorgi JV, et al.: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
2. Craib KJP, Strathdee SA, Hogg RS, et al.: Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection. J Infect Dis 1997, 176:798-800.
3. Kim S, Katzenstein D, Hughes M, et al.: HIV RNA serum levels, CD4 number and clinical outcomes in HIV infected subjects with 200 to 500 CD4 cells per cubic millimeter receiving zidovudine, with or without didanosine. International Congress on Antimicrobial Agents and Chemotherapy. Toronto, September 1997 [abstract I-138].
4. Babiker A for the Delta Coordinating Committee and Virology Group: Can HIV-1 RNA viral load be used as a surrogate for clinical endpoints in HIV disease? Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, October 1997 [abstract 103].
5. Hughes MD, Struthers L, Shear M: Changes in HIV-1 RNA from saquinavir use as predictors of risk of AIDS death. International Congress on Antimicrobial Agents and Chemotherapy. Toronto, September 1997 [abstract I-133].
6. Wauen LK, Nickens DJ, Chuang-Stein CJ, et al.: HIV-1 RNA viral burden at baseline or its reduction following antiretroviral therapy is highly correlated with reduced HIV-1 disease progression. Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1996 [abstract 452].
7. Freedman LS, Grubard BL, Schatzkin A: Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1993, 11:167-178.
8. O'Brien WA, Hartigen PM, Martin D, et al.: The relationship of treatment-induced changes in plasma HIV-1 RNA and CD4+ lymphocyte count to progression to AIDS in the Department of Veteran Affairs Zidovudine Study. N Engl J Med 1996, 334:426-431.
9. Phillips AN, Eron J, Bartlett J, et al.: Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. AIDS 1997, 11:169-175.
10. CAESAR Coordinating Committee: Randomised trial of the addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997, 349:1413-1421.
11. Daniels MJ, Hughes MD: Meta-analysis for the evaluation of potential surrogate markers. Stat Med 1997, 16:1965-1982.
12. D'Aquila R, Hughes MD, Johnson VA, et al.: Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med 1996, 124:1019-1030.
13. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
14. Gerstoft J on behalf of the AVANTI Study Group: AVANTI-2: a randomised, double-blind, comparative trial to evaluate the efficacy, safety and tolerance of combination antiretroviral regimens for the treatment of HIV-1 infection: AZT/3TC vs AZT/3TC/indinavir in antiretroviral naive patients. International Congress on Antimicrobial Agents and Chemotherapy. Toronto, September 1497 [abstract I-87].
15. Montaner JSG, Raboud JM, Roe S, et al.: Full suppression of viral replication to below 20 copies/ml is needed to achieve a durable antiviral response. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, October 1997 [abstract 104].
16. Carpenter CJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society - USA panel. JAMA 1997, 277:1962-1969.